FDA conditionally approves controversial Alzheimer’s drug despite uncertainty over effectiveness
The US Food and Drug Administration (FDA) has approved aducanumab (Aduhelm)—a drug which aims to delay clinical decline in patients with Alzheimer’s disease—despite concerns over a lack of…
